Gastroenterology & Endoscopy

Welcome to this week's Gastroenterology and Endoscopy News Roundup, where we bring you the most important updates and research findings for gastroenterology professionals. This episode covers five critical stories from the week of October 21-28, 2025, including new clinical guidelines, groundbreaking research on procedure safety, and the latest technological innovations in endoscopy.
1. AGA Releases Updated Barrett's Esophagus Surveillance Guideline
The American Gastroenterological Association has published a significant update to its clinical practice guideline on Barrett's esophagus surveillance. The new guideline represents a paradigm shift from uniform monitoring to a risk-based, individualized approach.
Clinical Impact: This guideline helps optimize resource allocation while improving early detection of neoplasia in higher-risk patients.

2. OCULUS Trial: Holding GLP-1 Agonists Before Endoscopy Reduces Risk
The OCULUS randomized controlled trial, presented at ACG 2025, provides the first RCT evidence on managing GLP-1/GIP-1 receptor agonists before upper endoscopy.

Clinical Impact: Strong evidence for holding these increasingly common medications before elective upper endoscopy to ensure patient safety and reduce aspiration risk.

3. Landmark Study Reveals 22% of Esophageal Cancers Missed on Endoscopy
A large population-based study from Finland and Sweden analyzed over 15,000 Barrett's esophagus patients and uncovered concerning rates of post-endoscopy esophagogastric cancers (PEEC).
Clinical Impact: Highlights urgent need for quality metrics in upper endoscopy, similar to adenoma detection rates in colonoscopy, to reduce missed cancers.

4. Fujifilm Launches ELUXEO 8000 Endoscopic Imaging System
FUJIFILM Healthcare Americas has unveiled its next-generation endoscopy platform with enhanced imaging capabilities.
Clinical Impact: Backward compatibility offers practical upgrade path for existing users while enhancing diagnostic and therapeutic capabilities.

5. FDA Approves Once-Monthly Omvoh Injection for Ulcerative Colitis
The FDA has approved a more convenient maintenance regimen for Eli Lilly's mirikizumab-mrkz (Omvoh) for moderately to severely active ulcerative colitis.
Clinical Impact: Simplified treatment regimen may improve patient adherence and reduce injection burden.

Sponsor
This episode is sponsored by DigestiveJobs.com
DigestiveJobs.com is the leading career resource for gastroenterology and endoscopy professionals. Whether you're seeking new opportunities, looking to hire talented clinicians, or exploring career advancement, DigestiveJobs.com connects you with the best positions and candidates in the field.
Visit DigestiveJobs.com to explore current opportunities and advance your career in gastroenterology.
https://www.gastroendopod.com

In this episode, we cover five crucial updates shaping gastroenterology and endoscopy practice in 2025. From the practice-changing ENDURO trial comparing endoscopic to surgical approaches for malignant gastric outlet obstruction, to the latest EASL hepatitis B management guidelines, AI applications in endoscopy, sedation innovations, and biomarker-driven approaches to IBS.
Resources & Links
ENDURO Trial & EUS-Guided Gastroenterostomy
ENDURO Study Protocol - Trials Journal
ENDURO Trial Results - The Lancet Gastroenterology & Hepatology
EUS-GE Overview - Gastroenterology & Endoscopy News
Prospective Study - Gastrointestinal Endoscopy
EASL 2025 Hepatitis B Guidelines
EASL HBV Guidelines 2025 - Journal of Hepatology
EASL Guidelines Summary - EASL Website
HBV Guidelines PDF - Hepatitis B Foundation
AI in Endoscopy
AI and Polyp Detection Review - PMC
AI-Assisted Colonoscopy Meta-Analysis - Annals of Internal Medicine
Use of AI in Colonoscopy - Gastrointestinal Endoscopy
Endoscopist Deskilling Study - The Lancet
Bibliometric Analysis - Frontiers in Medicine
Sedation Innovations
Remimazolam Review - Clinical Endoscopy
Remimazolam vs Propofol Meta-Analysis - British Journal of Anaesthesia
Remimazolam Comprehensive Review - World Journal of GI Endoscopy
Remimazolam Real-World Study - BMC Gastroenterology
Safety and Efficacy Comparison - BMC Anesthesiology
IBS Biomarkers & Microbiome
2025 Seoul Consensus on IBS - PMC
16S rRNA Microbiome Biomarkers for IBS - PMC
International Consensus on Microbiome Testing - Gut Microbiota for Health
Gut Microbiome Resilience Review - Frontiers in Microbiology
This podcast is for educational purposes only and does not constitute medical advice. Always consult current guidelines and use clinical judgment when making treatment decisions.

https://www.gastroendopod.com

In this quick-hit episode, we cover the freshest guidelines reshaping IBD, colorectal surveillance, gastric premalignancy, and gastroparesis management. Dive into cutting-edge research on AI for efficiency, targeted therapies, H. pylori strategies, advanced endoscopy, and cost-saving insights. Plus, spotlight on new tech warnings, bariatric devices, GERD diagnostics, and the game-changing FDA approval for subcutaneous Tremfya in UC. Perfect for busy GI pros—actionable takeaways to level up your practice.
Key Segments and Highlights:
Guidelines Rundown:BSG on IBD: Enhanced primary care pathways, CRC risk stratification, and patient adherence strategies to reduce post-colonoscopy cancers.
ACG on Gastric Premalignancy: First-ever guidance on atrophic gastritis, GIM, dysplasia—focus on H. pylori eradication and tailored surveillance.
BSG on Colorectal Surveillance: Clear start/stop criteria post-polypectomy and in IBD, with tips for better patient buy-in.
AGA on Gastroparesis: 12 recs for diagnosis (scintigraphy) and treatments (prokinetics, G-POEM)—emphasizing personalized, multidisciplinary care.
Rome/International on Gastroparesis: Aligns with AGA, adds psychosocial screening and global non-pharma standards. Takeaway: Download from AGA/ACG/BSG sites and audit your protocols.

Research Pulse:AI in Guideline Development (AGA Pilot): Cuts review time/costs dramatically for Crohn's biologics—use with human validation.
Targeted Drug Delivery: Nanoparticles for IBD/motility; watch for retention improvements.
H. pylori in MI Patients (ESC Data): Selective screening for high-risk antiplatelet users to curb GI bleeds.
EUS-Guided Gastroenterostomy: Standardization boosts success >90%; includes troubleshooting videos.
ASIDE Gastroenterology New Issue: Covers MMF in IBD, tofacitinib in peds UC, ESD aids, gastric cancer immunotherapy, and more.
Optical Enhancement Endoscopy RCT: 92% sensitivity for gastric metaplasia/neoplasia—upgrade for high-risk screens.
Hospital Affiliation Costs Study: Independents save 20-30% without quality loss; implications for value-based care. Takeaway: Subscribe to journals and experiment with AI cautiously.

Devices, Tech, and Approvals:Medical AI Warnings: Address biases in GI datasets; great for polyps, risky for diverse monitoring.
ESGE on Bariatric Endoscopy: Devices like balloons and duodenal resurfacing—10-15% weight loss, low AEs; await long-term RCTs.
New GERD Tools: AFS (EGJ integrity), Milan (manometry), pHoenix (AET), COuGH RefluX (symptoms), Lyon (integrated phenotyping)—revolutionize grading.
FDA Approval: SubQ Tremfya for UC: 50% endoscopic response at Week 12; convenient induction sans IV. Takeaway: Train on AI pitfalls and adopt one GERD tool quarterly.

Themes & Standouts: Personalization dominates, AI as a tool (not takeover), tech for precision. Revamp gastroparesis care, smart H. pylori screens, and embrace subQ Tremfya.
Resources: Links to guidelines, studies, and journals in the episode description. Submit Q&A via app/email. Next up: UEG Week previews!

Sponsored by digestivejobs.com
https://www.gastroendopod.com

This week's episode is packed with breakthrough developments that could reshape gastroenterology practice. We dive deep into the potentially transformative TL1A inhibitors showing remarkable results in IBD, explore the first-ever global consensus guidelines for managing IBD during pregnancy, and discuss how a simple blood test is revolutionizing colorectal cancer screening. Plus, we'll look at cutting-edge capsule technology that could disrupt traditional endoscopy and new research revealing the powerful connection between social factors and gut health.
#IBD #CrohnsDisease #UlcerativeColitis #Pregnancy #ColorectalCancer #Screening #Endoscopy #Innovation #Research #Guidelines #TL1A #BloodTest #Capsule #BrainGut #Microbiome
https://www.gastroendopod.com

🎧 Gastroenterology & Endoscopy Weekly Update | July 30, 2025
This week delivered game-changing developments across diagnostics, treatment, and clinical practice. From AI proving its effectiveness in real-world endoscopy to breakthrough therapies for previously "undruggable" cancers, here's what you need to know for your practice.
🔬 RESEARCH HIGHLIGHTS
AI Endoscopy Meta-Analysis: Comprehensive review of 569 studies shows AI significantly outperforms conventional endoscopy for GI tumor detection
MATTERHORN Trial Results: Imfinzi + chemotherapy reduces disease progression risk by 30% in early gastric/GEJ cancers
Thailand AI Approval: First country approves AI diagnostic system with 81% accuracy for gastric adenocarcinoma detection
💊 FDA & REGULATORY NEWS
Geneoscopy ColoSense: Simplified stool collection approved - eliminates scraping requirement, maintains 93% CRC sensitivity
Imfinzi Priority Review: Breakthrough Therapy designation for first potential perioperative immunotherapy in gastric cancer
VS-7375 Fast Track: KRAS G12D inhibitor for pancreatic cancer shows 52% response rate, 100% disease control
📋 PRACTICE UPDATES
New ASGE GERD Guidelines: TIF procedures now recommended as PPI alternative for appropriate candidates
Endohepatology Advances: EUS-guided procedures expanding options for liver disease management
AGA Gender Equity Framework: Six-domain approach to addressing workforce diversity challenges
⚡ CLINICAL TAKEAWAYS ✅ Prepare for AI-assisted endoscopy integration in your practice ✅ Consider simplified stool tests for screening-resistant patients
✅ Implement updated GERD procedural guidelines ✅ Explore endohepatology techniques for cirrhotic patients
🎯 KEY STATISTICS
44 million Americans aged 45-75 remain unscreened for colorectal cancer
Early gastric cancers missed in 4.5-25.8% of conventional endoscopies
100% sensitivity achieved for CRC screening in 45-49 age group with new collection method
📚 SOURCES All information compiled from peer-reviewed journals, FDA announcements, and major GI society publications from July 24-30, 2025.
⚠️ DISCLAIMER This content is for educational purposes only. Always consult primary sources and official guidelines for clinical decision-making.
#Gastroenterology #Endoscopy #AIinMedicine #ColorectalCancer #PancreaticCancer #GERD #ClinicalUpdates
https://www.gastroendopod.com